Evidence map›Paper›PMID 41392224›Full record

Trial reportAnnals of surgical oncology2026

The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial.

A W J Beerthuizen, T I M Snellen, S A Bartels, A Kuijer, C Poncet, C A Drukker, E J T Rutgers, M J T F D Vrancken Peeters, F H van Duijnhoven

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A W J Beerthuizen *Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
T I M Snellen *Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
S A BartelsDepartment of Surgery, Flevoziekenhuis, Almere, The Netherlands.
A KuijerDepartment of Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands.
C PoncetEuropean Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
C A DrukkerDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
E J T RutgersDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
M J T F D Vrancken PeetersDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
F H van DuijnhovenDepartment of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands. f.v.duijnhoven@nki.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of axillary ultrasound (AUS) in breast cancer staging varies across international guidelines, ranging from routine use to targeted implementation. This study evaluates the clinical utility of AUS in patients enrolled in the AMAROS trial.

methodsBetween 2001 and 2010, patients with early-stage breast cancer (cT1-T2N0M0) were enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) phase III non-inferiority AMAROS trial by 34 European sites. cN0 status was determined either by clinical examination (w/oAUS) or AUS. All patients underwent sentinel lymph node biopsy (SLNB); those with tumor-positive SLNB (SLNB+) were randomized to axillary lymph node dissection (ALND) and axillary radiotherapy (ART).

resultsIn total, 4806 patients were included, of which 1425 SLNB+ patients were randomized. AUS was performed in 3020 (63%) patients. No differences in SLNB results between AUS groups were observed; a positive SLNB was found in 30% of AUS patients and in 32% of w/oAUS patients (p = 0.266). For the SLNB+ patients randomized in the AMAROS trial (n = 1425), baseline characteristics were comparable, except for a significantly higher number of AUS patients in the trial enrollment years between 2006 and 2010 (63%) compared with 2001-2005 (38%) (p < 0.001). Axillary tumor load did not differ between AUS groups (p = 0.156).

conclusionsIn patients with cT1-2 breast cancer included in the AMAROS trial, sentinel lymph node involvement did not differ between patients who received pre-operative staging with AUS and those who were staged with clinical examination only.

Indexed as

Breast NeoplasmsLymph NodesAdultAgedAxillaFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoplasm StagingPrognosisSentinel Lymph Node BiopsyUltrasonographyAxillary stagingAxillary tumor burdenAxillary ultrasoundBreast cancerSentinel node biopsy

Identifiers

PMID41392224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.